Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -3.99
- The company has been able to generate a Return on Capital Employed (avg) of 3.62% signifying low profitability per unit of total capital (equity and debt)
Negative results in Sep 26
Stock is technically in a Mildly Bearish range
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 6 Cr (Micro Cap)
NA (Loss Making)
40
0.00%
0.04
-356.02%
1.15
Total Returns (Price + Dividend) 
Decipher Labs for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Decipher Labs Ltd Falls to 52-Week Low of Rs 4.81 as Sell-Off Deepens
For the third consecutive session, Decipher Labs Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 4.81 on 14 Oct 2026. This marks a significant 56.2% drop from its 52-week high of Rs 10.99, underscoring persistent selling pressure amid challenging fundamentals.
Read More
Decipher Labs Ltd Extends Losing Streak to 3 Sessions, Touches All-Time Low
For the third consecutive session, Decipher Labs Ltd has seen its share price decline sharply, hitting a new all-time low of Rs.4.81 on 14 Oct 2026. This latest drop comes amid a broader underperformance relative to its sector and benchmark indices, underscoring a challenging period for the micro-cap pharmaceutical company.
Read More Announcements 
Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2026.
14-Nov-2026 | Source : BSEUnaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30.09.2026.
Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday 14Th November 2026.
14-Nov-2026 | Source : BSE1. Un-audited Financial Results (Standalone and Consolidated) for the Quarter and half year ended 30th September 2026. (Attached).
Board Meeting Intimation for Meeting Scheduled To Be Held On 14Th November 2026.
10-Nov-2026 | Source : BSEDecipher Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 inter alia to consider and approve 1. Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th September 2026.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 2 FIIs (0.0%)
Ajjarapu Janakiram (16.43%)
Seshu Srinivas Akula (3.8%)
78.51%
Quarterly Results Snapshot (Consolidated) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is -28.77% vs -26.58% in Sep 2025
YoY Growth in quarter ended Sep 2026 is -70,450.00% vs 101.50% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -45.60% vs -21.71% in Sep 2024
Growth in half year ended Sep 2025 is -797.37% vs 86.85% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -45.32% vs -24.44% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -307.22% vs 66.32% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -37.86% vs -36.98% in Mar 2025
YoY Growth in year ended Mar 2026 is 39.37% vs -202.38% in Mar 2025